ライフサイエンスコーパス: mmHg

1 m no effect with self-monitoring alone (-1.0 mmHg [-3.3, 1.2]), to a 6.1 mmHg (-9.0, -3.2) reduction

2 ution resulted in IOP reduction of 5.4+/-1.0 mmHg on day 3 and peak IOP reduction of 6.6+/-1.3 mmHg o

3 BP responses (+6.3 +/- 1.0 vs. +3.5 +/- 1.0 mmHg, P = 0.011) were significantly augmented during MA

4 d by 61.6 mmHg in MD-NOS1KO mice versus 32.0 mmHg in WT mice (P<0.01) fed a high-salt diet.

5 e Ahmed group (47% reduction) and 13.6+/-5.0 mmHg in the Baerveldt group (57% reduction, P = 0.001).

6 The baseline IOPs were 20.4 +/- 6.0 mmHg and 21.2 +/- 6.1 (mean +/- standard deviation, p =

7 .9 mmHg during fasting (P = .002) and by 9.0 mmHg after the meal (P = .001).

8 ecision errors of -0.6 to 2.6 and 6.8 to 9.0 mmHg.

9 r by maintaining PPP at 20, 15, 10, 5, and 0 mmHg, and in laparotomy.

10 01 mmHg (% s)(-1) , n = 23 vs. 0.06 +/- 0.01 mmHg (% s)(-1) , n = 18; P = 0.003).

11 a greater transduction vs. OM (0.10 +/- 0.01 mmHg (% s)(-1) , n = 23 vs. 0.06 +/- 0.01 mmHg (% s)(-1)

12 Transduction was lowest in YW (0.02 +/- 0.01 mmHg (% s)(-1) , n = 23) and increased during beta-block

13 Transduction in PMW (0.07 +/- 0.01 mmHg (% s)(-1) , n = 23) was greater compared to YW (P =

14 ncreased during beta-blockade (0.11 +/- 0.01 mmHg (% s)(-1) ; P < 0.001).

15 altered during beta-blockade (0.06 +/- 0.01 mmHg (% s)(-1) ; P = 0.98).

16 = 79.51%), right atrial pressure (WMD: 1.01 mmHg, 95%CI: -0.93, 2.96, p = 0.307; Q = 44.88, I(2) = 9

17 unction (0.008 +/- 0.004 vs. 0.027 +/- 0.027 mmHg mul(-1) ).

18 g and IOPcc: height (-0.77 mmHg/m IOPg; 1.03 mmHg/m IOPcc), smoking (0.19 mmHg IOPg, -0.35 mmHg IOPcc

19 elf-reported diabetes (0.41 mmHg IOPg, -0.05 mmHg IOPcc), and black ethnicity (-0.80 mmHg IOPg, 0.77

20 ambulatory systolic blood pressure was 3.06 mmHg lower (95% CI 0.56-5.56 mmHg, p = 0.017) and mean a

21 e=0-60 mmHg, limit of detection=0.4 +/- 0.07 mmHg) and glucose (r(2)=0.989 +/- 0.009, concentration r

22 atients during acute migraine attacks (15.07 mmHg), painless period (14.10 mmHg), and the controls (1

23 he apelin receptor antagonist, F13A (0 +/- 1 mmHg; P < 0.01).

24 V1a receptor antagonist, SR 49059 (-1 +/- 1 mmHg; 1.1 +/- 1.1% total power, respectively; P < 0.001)

25 clinic -0.2 mmHg [-2.2, 1.8]; ambulatory 1.1 mmHg [-0.3, 2.5]).

26 l IOP in the upright position and 5.4+/- 3.1 mmHg in the supine position (p < .05).

27 ring alone (-1.0 mmHg [-3.3, 1.2]), to a 6.1 mmHg (-9.0, -3.2) reduction when monitoring was combined

28 Hg) in the ALPI group (P < 0.001) and by 6.1 mmHg (95% CI, 5.1-7.1 mmHg) in the medication group (P <

29 (P < 0.001) and by 6.1 mmHg (95% CI, 5.1-7.1 mmHg) in the medication group (P < 0.001).

30 toregulation varied substantially (mean 74.1 mmHg, SD 17.6 mmHg).

31 ood intake but increased MAP and HR (8 +/- 1 mmHg and 33 +/- 7 bpm), while Vo2 increased by approxima

32 elin-13 significantly increased ABP (9 +/- 1 mmHg) compared to saline (-1 +/- 2mmHg; P < 0.001), whic

33 We found that elevation of SBP levels by 1 mmHg due to our genetic score was associated with a 2% i

34 CO2 are particularly potent to change CBF (1 mmHg variation in arterial CO2 changes CBF by 3%-4%), th

35 milar increase in type 2 diabetes risk per 1 mmHg of genetic elevation in SBP (odds ratio 1.02, 95% C

36 ivity (3.4 +/- 0.4 to 5.1 +/- 0.8 ml min(-1) mmHg(-1) ).

37 ivity (3.3 +/- 0.3 to 4.4 +/- 0.4 ml min(-1) mmHg(-1) ).

38 For progressing eyes, each 1-mmHg higher average in IOP during follow-up was associat

39 (DeltaIOP = 0.46-mmHg reduction for every 1-mmHg increment in baseline IOP; 95% confidence interval

40 attacks (15.07 mmHg), painless period (14.10 mmHg), and the controls (15,73 +/- 0,81).

41 Associations were similar for each 10 mmHg increment in diastolic blood pressure (DBP) (p < 0.

42 Every 10 mmHg drop from baseline in mean arterial pressure associ

43 /=21 mmHg, >/=30 mmHg, and increase of >/=10 mmHg from documented IOP recordings (or use of treatment

44 , hepatic venous pressure gradient [HVPG] 10 mmHg or greater), despite achieving sustained virologica

45 discovered a severe hypoxic event (pO2 < 10 mmHg) after the termination of seizures.

46 c disc excavation (20%), relatively low (<10 mmHg) intraocular pressure (22%), and optic nerve hypopl

47 ieve a sustained systolic blood pressure <10 mmHg, cardiac arrest.

48 ressure (OR, 0.74; 95% CI, 0.65-0.84, per 10 mmHg increase), total cholesterol (OR, 0.87; 95% CI, 0.8

49 for generating pressures that can reach 100 mmHg through the creation of a large gel-fluid phase.

50 usion flow indices (0.43 vs.0.32 ml/min/100g/mmHg,p=0.049).

51 mean arterial pressure </=92 mmHg or 102-107 mmHg, respectively) to the US Renal Data System and Soci

52 nts was -0.33 mmHg (standard deviation, 3.11 mmHg).

53 ering bleb and uncontrolled IOP (34.5 +/- 11 mmHg), under maximum topical treatment, in a period of 2

54 onths after Nd: Yag capsulotomy (34.5 +/- 11 mmHg).

55 over the intraluminal pressure range, 30-110 mmHg.

56 reasing clinic systolic BP: 2% in the 90-110 mmHg group, 17% in the 110-119 mmHg group, 34% in the 12

57 tion with no evidence of a nadir down to 115 mmHg (p < 0.001).

58 in the 90-110 mmHg group, 17% in the 110-119 mmHg group, 34% in the 120-129 mmHg group, and 66% in th

59 ifts to the right; 120 +/- 14 vs. 112 +/- 12 mmHg, P < 0.005), and 3) the maximum R-R interval respon

60 n the 110-119 mmHg group, 34% in the 120-129 mmHg group, and 66% in the 130-139 mmHg group.

61 nd normal systolic blood pressure (SBP < 130 mmHg).

62 gher and home systolic blood pressure of 130 mmHg or higher on permitted background drugs of angioten

63 e 120-129 mmHg group, and 66% in the 130-139 mmHg group.

64 monary hypertension (62 +/- 13 and 53 +/- 14 mmHg at 3 and 6 weeks, respectively) with reduction of t

65 measures included IOP thresholds of 6 to 14 mmHg and 6 to 21 mmHg and same thresholds allowing for m

66 ndardized predialysis systolic BP of 110-140 mmHg (intensive arm) or 155-165 mmHg (standard arm).

67 those with systolic blood pressure below 140 mmHg.

68 23-32 weeks of gestation, systolic BP >/=140 mmHg or diastolic BP >/=90 mmHg, new onset protein/creat

69 a general recommendation of systolic BP <140 mmHg and diastolic BP <90 mmHg.

70 P decreased from 160 mmHg at baseline to 143 mmHg at 4.5 months.

71 est and largest waist circumference being 15 mmHg.

72 blood pressure (DBP) (p < 0.001) or each 15 mmHg increment in pulse pressure (PP) (p < 0.001).

73 target IOP at </=21, </=17 and </=15 mmHg; complete and qualified success endpoint rates.

74 een IOP before Nd: YAG laser capsulotomy (16 mmHg +/- 3 mmHg) and the respective one, 2 to 6 months a

75 (IQR: 12-18) before treatment to 13 (10-16) mmHg after SVR (reduction of 2.1 +/- 3.2 mmHg; P < .01).

76 onoverhydrated patients with syst-BP=130-160 mmHg as the reference category; >200,000 FO measurements

77 gen peroxide, respectively, than TiO2 at 160 mmHg.

78 ntensive arm, systolic BP decreased from 160 mmHg at baseline to 143 mmHg at 4.5 months.

79 syst-BP) categories (<130, 130-160, and >160 mmHg), with nonoverhydrated patients with syst-BP=130-16

80 P of 110-140 mmHg (intensive arm) or 155-165 mmHg (standard arm).

81 ambulatory diastolic blood pressure was 2.17 mmHg lower (95% CI 0.62-3.72, p = 0.006) among people in

82 readings of <6 mmHg with vision loss or >17 mmHg without glaucoma medications (complete success) at

83 edications and higher baseline sBP up to 170 mmHg.

84 ressure (IOP) outside the target range (5-18 mmHg) or reduced <20% from baseline for 2 consecutive vi

85 mean IOP of 13.41 +/- 2.22 mmHg (range 8-18 mmHg).

86 ed the proportion of subjects with IOP </=18 mmHg consistently at all 9 time points and the proportio

87 riates, Indian persons had, on average, 0.18-mmHg higher CH levels than in Chinese (95% confidence in

88 Hg/m IOPg; 1.03 mmHg/m IOPcc), smoking (0.19 mmHg IOPg, -0.35 mmHg IOPcc), self-reported diabetes (0.

89 Pre-operative IOP was 17.75 +/- 2.19 mmHg (range 12-21 mmHg).

90 or ambulatory sBP in this group (clinic -0.2 mmHg [-2.2, 1.8]; ambulatory 1.1 mmHg [-0.3, 2.5]).

91 the next higher GI group had a 1.69 +/- 0.2 mmHg larger IOP decrease.

92 trol groups (60.5+/-8.7 mmHg and 62.9+/-10.2 mmHg respectively, p = 0.393), and also no statistically

93 rats during tiron infusion averaged 13 +/- 2 mmHg (n = 12; P < 0.001); the attenuating effect of tiro

94 (supine, 17 +/- 2 vs. microgravity, 13 +/- 2 mmHg) were reduced in acute zero gravity, although not t

95 with a between-group difference of 14 +/- 2 mmHg by week 3 (P < 0.01), which was accompanied by impr

96 supine (seated, 4 +/- 1 vs. supine, 15 +/- 2 mmHg).

97 the superficial epigastric artery (21 +/- 2 mmHg; P < 0.01 vs. tiron).

98 P) compared to usual care at 12 months (-3.2 mmHg, [95% CI -4.9, -1.6 mmHg]).

99 16) mmHg after SVR (reduction of 2.1 +/- 3.2 mmHg; P < .01).

100 e (supine, 7 +/- 3 vs. microgravity, 4 +/- 2 mmHg) and ICP (supine, 17 +/- 2 vs. microgravity, 13 +/-

101 cular pressure (IOP) for SLT 1 = 20.3+/- 5.2 mmHg and SLT 2 = 19.4 +/- 5.0 was reduced to 16.4 +/- 3.

102 r hypoxic exposure, the rise in PASP was 6.2 mmHg greater in the ID group (absolute rises 16.1 and 10

103 .7) in the NTG group (n = 13) and 11.3 (2.2) mmHg in the larger control group (n = 51) (P = 0.24).

104 d a hydraulic permeability of 130 ml/hr/m(2)/mmHg, which is more than 3 fold greater than existing po

105 Each 20 mmHg increment in SBP was associated with a 26% higher r

106 ratoplasty: preoperative glaucoma or IOP >20 mmHg (adjusted hazard ratio [HR], 1.56; P < 0.001), pene

107 IOP of 23 mmHg or more at time 0, IOP of 20 mmHg or more at 2 and 8 hours, and IOP of 34 mmHg or les

108 n SBP and risk of mitral stenosis (HR per 20 mmHg higher SBP 1.03; CI 0.93, 1.14; p = 0.58).

109 ive IOP was 17.75 +/- 2.19 mmHg (range 12-21 mmHg).

110 ; history of OHT in the other eye: IOP >/=21 mmHg (aHR, 2.68), >/=30 mmHg (aHR, 4.86) and prior/curre

111 he mean annual incidence rates for OHT >/=21 mmHg and OHT >/=30 mmHg are 14.4% (95% confidence interv

112 T with intraocular pressures (IOPs) of >/=21 mmHg, >/=30 mmHg, and increase of >/=10 mmHg from docume

113 ctive treatment for these patients (IOP < 21 mmHg).

114 Complete success rates at </= 21 mmHg target IOP were 65% and 70%, at </=17 mm Hg 60% and

115 al success (intraocular pressure [IOP] </=21 mmHg and reduced >/=20% from baseline, IOP >5 mmHg, no r

116 a for complete success were IOP >5 and </=21 mmHg with at least a 20% reduction below medicated basel

117 P < 0.001), and qualified success (IOP </=21 mmHg with medication) was achieved in 35.0% and 7.5%, re

118 Complete success (IOP </=21 mmHg without medication) was achieved in 35.0% eyes of t

119 ualified success was defined as an IOP of 21 mmHg or less with medication.

120 Complete success was defined as an IOP of 21 mmHg or less without medication, and qualified success w

121 Failure was defined as an IOP more than 21 mmHg despite additional medications or requiring glaucom

122 d as intraocular pressure (IOP) more than 21 mmHg or reduced by less than 20% from baseline, IOP of 5

123 d intraocular pressure (IOP) of more than 21 mmHg were enrolled.

124 d IOP thresholds of 6 to 14 mmHg and 6 to 21 mmHg and same thresholds allowing for medications (quali

125 n -6 diopters (D) to 6 D, and IOP of 6 to 21 mmHg.

126 ollow-up showed a mean IOP of 13.41 +/- 2.22 mmHg (range 8-18 mmHg).

127 l visual field, and intraocular pressure >22 mmHg).

128 n relation to the POAG subtypes with IOP <22 mmHg (MVRR, 1.93; 95% CI, 1.09-3.43) and early paracentr

129 ned by intraocular pressure (IOP; >/= or <22 mmHg) or visual field (VF) loss pattern at diagnosis (pe

130 arterial pressure falling by a median of 22 mmHg (interquartile range, 14.3-31.9 mmHg) and dropping

131 I: 1.45, 3.50 mmHg) increase in SBP and 2.22-mmHg (95% CI: 1.69, 2.75 mmHg) increase in DBP, respecti

132 Key eligibility included washout IOP of 23 mmHg or more at time 0, IOP of 20 mmHg or more at 2 and

133 ost sensors, ranging in amplitude from 5-230 mmHg.

134 s (dB) MD under target IOPs of 6, 15, and 24 mmHg, respectively, over 5 years.

135 t 1 of 7 levels (6, 9, 12, 15, 18, 21, or 24 mmHg) over the next 5 years.

136 in 6 male piglets and maintaining PPP at 25 mmHg, CVP was measured 3 times at each of 9 levels of ai

137 r pulmonary pressure (57 +/- 11 vs 52 +/- 27 mmHg) and higher lung allocation scores (70 +/- 9 vs 51

138 no significant differences: 0.54 mmHg, -1.28 mmHg, -0.33 mmHg for the 0.125 % atropine, 0.25 % atropi

139 ), FBG -2.40 mg/dL (-3.59; -1.21), SBP -4.29 mmHg (-5.73, -2.84), DBP -2.56 mmHg (-3.40, 1.71), HDL +

140 d IOP by 6.3+/-1.0, 6.7+/-0.3, and 6.7+/-0.3 mmHg on days 3, 5, and 8, respectively.

141 5% CI for difference in change, -8.3 to -0.3 mmHg, P = 0.035).

142 he Ahmed group (44% reduction) and 1.2+/-1.3 mmHg in the Baerveldt group (61% reduction, P = 0.03).

143 on day 3 and peak IOP reduction of 6.6+/-1.3 mmHg on day 5.

144 Mean ICP in supine was 10.3 mmHg (SD = 2.7) in the NTG group (n = 13) and 11.3 (2.2)

145 pressor (control: 24 +/- 2, GsMTx4: 14 +/- 3 mmHg, P < 0.01), cardioaccelerator and renal sympathetic

146 IOP in the upright position and 7.9 +/- 2.3 mmHg lower in the supine position (p < .05).

147 ice (systolic BP 167 +/- 4.2 vs. 180 +/- 3.3 mmHg, p < 0.05), which was associated with decreased aor

148 ia (arterial CO2 tension: approximately 46.3 mmHg), depressed the CMRO2 ( approximately 17%, P = 0.04

149 erfused with TOLB (199 +/- 16 ms; 92 +/- 5.3 mmHg) than in LWHs without TOLB (109 +/- 14 ms, P = 0.00

150 mmHg (95% confidence interval [CI], 3.5-6.3 mmHg) in the ALPI group (P < 0.001) and by 6.1 mmHg (95%

151 han true intracameral IOP by approximately 3 mmHg in vitro and 5 mmHg in vivo.

152 ore Nd: YAG laser capsulotomy (16 mmHg +/- 3 mmHg) and the respective one, 2 to 6 months after Nd: Ya

153 int value of 15.2 (+/-3.2) and 15.8 (+/-2.3) mmHg in MMC and OLO, respectively.

154 ssure was 20 mm Hg (median, 16; range, 15-30 mmHg).

155 other eye: IOP >/=21 mmHg (aHR, 2.68), >/=30 mmHg (aHR, 4.86) and prior/current use of IOP-lowering d

156 dence rates for OHT >/=21 mmHg and OHT >/=30 mmHg are 14.4% (95% confidence interval [CI], 13.4-15.5)

157 nificant risk factors for incident OHT >/=30 mmHg included systemic hypertension (adjusted hazard rat

158 ive elevation in intraocular pressure (>/=30 mmHg) was documented in 3 eyes (4 %).

159 ocular pressures (IOPs) of >/=21 mmHg, >/=30 mmHg, and increase of >/=10 mmHg from documented IOP rec

160 he Icare HOME and GAT measurements was -0.33 mmHg (standard deviation, 3.11 mmHg).

161 nt differences: 0.54 mmHg, -1.28 mmHg, -0.33 mmHg for the 0.125 % atropine, 0.25 % atropine and contr

162 unmedicated intraocular pressure (IOP) 21-33 mmHg and were undergoing phacoemulsification cataract su

163 ed significantly with reduction in IOP (1.33-mmHg reduction for every 1-mm increment in AOD500; P = 0

164 mmHg or more at 2 and 8 hours, and IOP of 34 mmHg or less at all time points; no prior incisional sur

165 mHg/m IOPcc), smoking (0.19 mmHg IOPg, -0.35 mmHg IOPcc), self-reported diabetes (0.41 mmHg IOPg, -0.

166 ulmonary artery systolic pressure (PASP) >35 mmHg and/or tricuspid regurgitant velocity (TRV) >2.5 m/

167 SH (PaO2 = 40-54 mmHg) or sASH (PaO2 = 25-36 mmHg), (1) mASH induced a serotonin-dependent pMF and (2

168 decreases in oxygen above a PETCO2 of 32-37 mmHg but being limited below this threshold.

169 no longer compensate below a PETCO2 of 32-37 mmHg.

170 estoring mean arterial pressure from 0 to 37 mmHg.

171 tal pressure was dropped from 33.08 +/- 1.38 mmHg preoperatively to 20.18 +/- 0.83 mmHg postoperative

172 099, -0.618]; P = 3E-12 and diastolic -0.394 mmHg [-0.534, -0.254]; P = 4E-8).

173 ring wake periods (SBP, +1.6 mmHg; DBP, +1.4 mmHg).

174 , 15 +/- 2 vs. 24 h head-down tilt, 15 +/- 4 mmHg).

175 Hg), but lower than in adult SHRs (152 +/- 4 mmHg; P < 0.05).

176 ats during saline infusion averaged 31 +/- 4 mmHg, whereas the peak EPR in these rats during tiron in

177 xia (arterial O2 tension: approximately 38.4 mmHg), severe hypercapnia (arterial CO2 tension: approxi

178 bimatoprost group compared with -4.2 to -6.4 mmHg for the timolol group over 6 months.

179 reduction from baseline IOP of -3.2 to -6.4 mmHg was observed for the bimatoprost group compared wit

180 he microstent group versus downward arrow5.4 mmHg in controls (P < 0.001), with 85% of microstent sub

181 Mean IOP reduction was downward arrow7.4 mmHg for the microstent group versus downward arrow5.4 m

182 to significantly affect the error by up to 4 mmHg over the sample size.

183 al blood partial pressure of CO2 of above 40 mmHg and is a feature of chronic lung disease.

184 xternal cuff pressures (0, 10, 20, 30 and 40 mmHg) on the whole arm to obtain arterial volume distens

185 external cuff pressures of 10, 20, 30 and 40 mmHg, the overall changes in arterial volume distensibil

186 n each patient alternately to 10, 20, and 40 mmHg.

187 and 21% total venous area) with hypoxia (40 mmHg P ETC O2; P < 0.001) and decreasing diameter (6.9%

188 35 mmHg IOPcc), self-reported diabetes (0.41 mmHg IOPg, -0.05 mmHg IOPcc), and black ethnicity (-0.80

189 eduction in IOP at 6 months (DeltaIOP = 0.46-mmHg reduction for every 1-mmHg increment in baseline IO

190 A three-week hypoxia acclimation (48 mmHg) resulted in significant up-regulation of Hbalpha-2

191 y moving-average Ni was associated with 2.48-mmHg (95% CI: 1.45, 3.50 mmHg) increase in SBP and 2.22-

192 ) and root-mean-squared-error of 7.6 +/- 0.5 mmHg after a best-case calibration.

193 e IOP; 95% confidence interval [CI], 0.4-0.5 mmHg; P < 0.001).

194 and root-mean-squared-error of 14.6 +/- 1.5 mmHg (p < 0.05).

195 Mean medication use was 1.8+/-1.5 mmHg in the Ahmed group (44% reduction) and 1.2+/-1.3 mm

196 pressor (control: 24 +/- 5, GsMTx4: 12 +/- 5 mmHg, P < 0.01), cardioaccelerator and renal sympathetic

197 s errors but precision errors of 8.2 to 12.5 mmHg (p </= 0.01).

198 sting ABP is higher in young SHRs (122 +/- 5 mmHg) than in age-matched Wistar-Kyoto rats (99 +/- 5 mm

199 and diastolic blood pressure (-2.6 +/- 14.5 mmHg, P = 0.04), and cardiovascular risk (13% relative r

200 Cadaver eye IOP measurements were 3.1+/-2.5 mmHg lower than intracameral IOP in the upright position

201 OP by 10.5+/-1.4, 11.1+/-4.0, and 10.0+/-2.5 mmHg on days 3, 5, and 8, respectively.

202 t TOLB (109 +/- 14 ms, P = 0.005; 65 +/- 6.5 mmHg, P = 0.01).

203 n in age-matched Wistar-Kyoto rats (99 +/- 5 mmHg), but lower than in adult SHRs (152 +/- 4 mmHg; P <

204 l IOP by approximately 3 mmHg in vitro and 5 mmHg in vivo.

205 mHg and reduced >/=20% from baseline, IOP >5 mmHg, no reoperation for glaucoma, no loss of light-perc

206 low IOP included all patients with IOP </=5 mmHg on 3 or more consecutive visits 3 months or later a

207 ced by less than 20% from baseline, IOP of 5 mmHg or less, reoperation for glaucoma, or loss of light

208 dian [interquartile range] 6 mmHg [4-7] vs 5 mmHg [3-7]; p = 0.04), with a success rate of 76%.

209 he HOME and GAT measurements agreed within 5 mmHg in 116 of 127 participants (91.3%); 2 participants

210 raocular pressure (IOP) measurement within 5 mmHg of Goldmann applanation tonometry (GAT).

211 ssociated with 2.48-mmHg (95% CI: 1.45, 3.50 mmHg) increase in SBP and 2.22-mmHg (95% CI: 1.69, 2.75

212 cant increase of N-cadherin AJ density at 50 mmHg, whereas vasodilatation induced by ACh (10(-5) m) w

213 with oscillation amplitudes that exceeded 50 mmHg, depending on the conditions of mechanical ventilat

214 siologically relevant mechanical loading (50 mmHg systolic, 10% biaxial stretch) in either a low- or

215 d inflated to a constant cuff pressure of 50 mmHg).

216 ssure of oxygen (PETCO2) ranging from 40-500 mmHg.

217 d 23% total venous area) with hyperoxia (500 mmHg PETCO2; P < 0.001) to the same extent.

218 so revealed no significant differences: 0.54 mmHg, -1.28 mmHg, -0.33 mmHg for the 0.125 % atropine, 0

219 agonist injections before mASH (PaO2 = 40-54 mmHg) or sASH (PaO2 = 25-36 mmHg), (1) mASH induced a se

220 stoperatively [P = 0.792]; IOP, 14.94+/-3.55 mmHg preoperatively vs. 17.72+/-5.88 mmHg 1 month postop

221 g mechanical stimulation at a pressure of 55 mmHg for 50 milliseconds (p < 0.05).

222 1), SBP -4.29 mmHg (-5.73, -2.84), DBP -2.56 mmHg (-3.40, 1.71), HDL +0.85 mg/dL (-0.10, 1.60), and T

223 essure was 3.06 mmHg lower (95% CI 0.56-5.56 mmHg, p = 0.017) and mean ambulatory diastolic blood pre

224 astolic BP was lower on average by 0.95/0.57 mmHg, and odds of hypertension were lower by 14%.

225 lding fetal mean P(aO2) levels (11.5 +/- 0.6 mmHg) similar to those measured in human fetuses of hypo

226 r measured on live human eyes was 5.2 +/-1.6 mmHg lower than intracameral IOP in the upright position

227 lood pressure during wake periods (SBP, +1.6 mmHg; DBP, +1.4 mmHg).

228 the clinical measurements of CH (10.6+/-1.6 mmHg; P = 0.670) or CRF (10.3+/-1.7 mmHg; P = 0.103) bet

229 at 12 months (-3.2 mmHg, [95% CI -4.9, -1.6 mmHg]).

230 aried substantially (mean 74.1 mmHg, SD 17.6 mmHg).

231 +/-2.9 mmHg) and MSICS (DeltaIOP = 2.6+/-2.6 mmHg; P = 0.70).

232 raocular pressure (32.2+/-9.7 vs. 17.6+/-3.6 mmHg; P < 0.001), cup-to-disc ratio (0.65+/-0.27 vs. 0.4

233 essure during sleep opportunities (SBP, +5.6 mmHg; DBP, +1.9 mmHg) and, to a lesser extent, by raised

234 II, mean arterial pressure increased by 61.6 mmHg in MD-NOS1KO mice versus 32.0 mmHg in WT mice (P<0.

235 s and was found to reduce IOP initially by 6 mmHg and then by progressively smaller amounts for more

236 ve intraocular pressure (IOP) readings of <6 mmHg with vision loss or >17 mmHg without glaucoma medic

237 OP reduction (median [interquartile range] 6 mmHg [4-7] vs 5 mmHg [3-7]; p = 0.04), with a success ra

238 (2)=0.985 +/- 0.01, concentration range=0-60 mmHg, limit of detection=0.4 +/- 0.07 mmHg) and glucose

239 Intracameral IOP ranged between 5 and 60 mmHg.

240 range, 14.3-31.9 mmHg) and dropping below 60 mmHg in 24% of sessions.

241 low an absolute mean arterial pressure of 60 mmHg.

242 d to high-altitude hypoxia (3801 m, PaO2: 60 mmHg) for 110 days.

243 up were 2.01 +/- 0.69 mmHg and 1.97 +/- 0.68 mmHg (p = 0.839).

244 oup and the control group were 2.01 +/- 0.69 mmHg and 1.97 +/- 0.68 mmHg (p = 0.839).

245 .6+/-1.6 mmHg; P = 0.670) or CRF (10.3+/-1.7 mmHg; P = 0.103) between the ethnic groups.

246 n the ID group (absolute rises 16.1 and 10.7 mmHg, respectively; 95% CI for difference, 2.7-9.7 mmHg,

247 9 mg/dL, P < 0.001), systolic (-8.9 +/- 18.7 mmHg, P < 0.001) and diastolic blood pressure (-2.6 +/-

248 ia (arterial CO2 tension: approximately 58.7 mmHg), but not mild-hypercapnia (arterial CO2 tension: a

249 tween the NTG and control groups (60.5+/-8.7 mmHg and 62.9+/-10.2 mmHg respectively, p = 0.393), and

250 respectively; 95% CI for difference, 2.7-9.7 mmHg, P = 0.001).

251 pants (1.6%) had a difference of more than 7 mmHg.

252 mHg; either nighttime hypertension >/=120/70 mmHg or daytime hypertension; and 24-hour hypertension >

253 The mean IOPg was 15.72 mmHg (95% confidence interval [CI], 15.70-15.74 mmHg), a

254 g (95% confidence interval [CI], 15.70-15.74 mmHg), and the mean IOPcc was 15.95 mmHg (15.92-15.97 mm

255 ase in SBP and 2.22-mmHg (95% CI: 1.69, 2.75 mmHg) increase in DBP, respectively.

256 , and black ethnicity (-0.80 mmHg IOPg, 0.77 mmHg IOPcc).

257 sociation with IOPg and IOPcc: height (-0.77 mmHg/m IOPg; 1.03 mmHg/m IOPcc), smoking (0.19 mmHg IOPg

258 Mean preoperative IOP was 31.4+/-10.8 mmHg on 3.1+/-1.0 glaucoma medications.

259 ann IOP error is increased an additional 2.8 mmHg lower in the supine position.

260 oups were similar: 24.5+/-3.0 and 24.4+/-2.8 mmHg, respectively (P > 0.05); mean medications were 1.3

261 n controls (absolute reductions 11.1 and 6.8 mmHg, respectively; 95% CI for difference in change, -8.

262 0.05 mmHg IOPcc), and black ethnicity (-0.80 mmHg IOPg, 0.77 mmHg IOPcc).

263 rtension; and 24-hour hypertension >/=130/80 mmHg) or by home BP monitoring (hypertension >/=135/85 m

264 - 1.38 mmHg preoperatively to 20.18 +/- 0.83 mmHg postoperatively (p < 0.001).

265 y home BP monitoring (hypertension >/=135/85 mmHg).

266 hypertension (daytime hypertension >/=135/85 mmHg; either nighttime hypertension >/=120/70 mmHg or da

267 nd had lower blood pressure (systolic -0.859 mmHg [-1.099, -0.618]; P = 3E-12 and diastolic -0.394 mm

268 +/-3.55 mmHg preoperatively vs. 17.72+/-5.88 mmHg 1 month postoperatively [P = 0.197]).

269 eep opportunities (SBP, +5.6 mmHg; DBP, +1.9 mmHg) and, to a lesser extent, by raised blood pressure

270 ect in T1D patients (112 +/- 10 to 109 +/- 9 mmHg, P = 0.049) without impacting arterial stiffness, F

271 aration in systolic BP between arms was 12.9 mmHg.

272 ng phacoemulsification (DeltaIOP = 2.7+/-2.9 mmHg) and MSICS (DeltaIOP = 2.6+/-2.6 mmHg; P = 0.70).

273 n of 22 mmHg (interquartile range, 14.3-31.9 mmHg) and dropping below 60 mmHg in 24% of sessions.

274 The IOP decreased by 4.9 mmHg (95% confidence interval [CI], 3.5-6.3 mmHg) in the

275 Mean IOP was 16.6+/-5.9 mmHg in the Ahmed group (47% reduction) and 13.6+/-5.0 m

276 sed intragastric pressure by a median of 6.9 mmHg during fasting (P = .002) and by 9.0 mmHg after the

277 IOP is increased or decreased by 3, 6, and 9 mmHg from the level attained in the trials.

278 elevated BP--defined as documented BP>140/90 mmHg measured during an ambulatory, nonemergency departm

279 12), hypertension (blood pressure >/= 140/90 mmHg or taking medication), obesity (body mass index >/=

280 s having at least two BP readings of >140/90 mmHg or those with evidence of CKD were excluded.

281 h despite ramipril at 10 mg/d and BP<140/90 mmHg were treated for four 8-week periods with PARI (2 m

282 t known to be hypertensive or have BP>140/90 mmHg.

283 ystolic BP >/=140 mmHg or diastolic BP >/=90 mmHg, new onset protein/creatinine ratio >0.30 g/g, and

284 f systolic BP <140 mmHg and diastolic BP <90 mmHg.

285 the lumen pressure was raised from 50 to 90 mmHg, both the density and the average size of N-cadheri

286 ual BP control (mean arterial pressure </=92 mmHg or 102-107 mmHg, respectively) to the US Renal Data

287 70-15.74 mmHg), and the mean IOPcc was 15.95 mmHg (15.92-15.97 mmHg).

288 ding pulmonary arterial pressure (WMD: -0.97 mmHg, 95%CI: -4.39, 2.44, p = 0.577; Q = 14.64, I(2) = 7

289 d the mean IOPcc was 15.95 mmHg (15.92-15.97 mmHg).

290 A multivariate regression demonstrated each mmHg of IOP increase would result in 3ng/mL lower concen

291 erged as our top finding (a 0.04 increase in mmHg of systolic blood pressure for 1 standard deviation

292 ns (Lat-B vehicle; 0.0023 +/- 0.0005 muL/min/mmHg) were similar and stable over 2 hours (p > 0.1 for

293 -buffered saline (0.0027 +/- 0.00036 muL/min/mmHg; mean +/- SD) and 0.02% ethanol perfusions (Lat-B v

294 ) ms mmHg(-1) ] compared to NC [11 (8-15) ms mmHg(-1) ; P = 0.002].

295 nd HTN patients [5(3-8), 4 (2-7), 6 (4-9) ms mmHg(-1) ] compared to NC [11 (8-15) ms mmHg(-1) ; P = 0

296 ificantly (19.2 +/- 7.5 vs. 32.9 +/- 16.6 ms/mmHg, P < 0.005), 2) the systolic blood pressure thresho

297 02 mum/cm; P < 0.001), higher IOP (-0.03 mum/mmHg; P < 0.001), and regular smoking (-0.27 mum vs. non

298 sure were 0.010, 0.029, 0.054 and 0.108% per mmHg for the arm at the horizontal level, and 0.026, 0.0

299 hich were 0.016, 0.043, 0.116 and 0.281% per mmHg (all P < 0.01).

300 evel, and 0.026, 0.071, 0.170 and 0.389% per mmHg for the arm at 45 degrees from the horizontal level